Background: Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown.
introduction
Identifying a reliable biomarker to predict the efficacy of adjuvant endocrine therapy for hormone receptor-positive breast cancer on an individual basis would be an important step forward to the practice of personalized medicine [1] . Current approaches focus on single time point biomarker analysis of the diagnostic sample, with several molecular portraits being validated to better define prognosis and treatment decision making [2] [3] [4] . An alternative approach is to treat patients with an endocrine agent for a short time window, usually 2-4 weeks, before surgery to identify tumors that are responsive to treatment, with the assumption that biomarker responsiveness predicts a lower risk of relapse and death. However, compared with neoadjuvant chemotherapy studies [5] , fewer preoperative endocrine therapy trials have so far assessed the prognostic significance of post-neoadjuvant therapy tumor characteristics [6, 7] . In addition, this approach might help to improve the efficiency and reduce the costs of screening new agents once the association between biomarker response and survival had been validated.
Among these putative predictive biomarkers, Ki-67 labeling index (LI), a reliable measure of tumor proliferative fraction [8] has extensively been studied and shown to have independent prognostic significance in several large clinical trials of adjuvant endocrine therapy [9] . Moreover, preoperative studies have demonstrated that a reduction in Ki-67 LI predicts tumor shrinkage to hormonal agents in breast cancer [10, 11] . Thus, a substantial reduction of Ki-67 LI after a short-term challenge test of a few weeks of hormonal treatment might be a simple and unexpensive way to select women with estrogen receptor (ER)-positive breast cancer who may not benefit from adjuvant chemotherapy. Dowsett et al. [6] have recently shown that higher Ki-67 LI after 2 weeks of neoadjuvant treatment with either tamoxifen or anastrozole or their combination was associated with shorter recurrence-free survival after a median of 37 months in 158 postmenopausal women with operable or locally advanced breast cancer participating in the IMPACT trial. Ellis et al. [7] have recently shown that postmenopausal patients with stage 2 or 3 disease after neoadjuvant endocrine therapy with aromatase inhibitors or tamoxifen for 4 months and a low-risk biomarker profile in the surgical specimen, including lower Ki-67 LI, have a lower risk of relapse and prolonged breast cancer-specific survival [12] and are therefore unlikely to benefit from adjuvant chemotherapy.
In the present study, we assessed the prognostic effect of post-treatment Ki-67 LI on invasive or recurrence-free and overall survival after a median follow-up of 7.2 years (range 1-9.2 years) in 120 pre-and postmenopausal women with operable stage I-II ER-positive breast cancer who participated in a window-of-opportunity, randomized dose-ranging trial of tamoxifen administered for 4 weeks before surgery [12] .
subjects and methods
The present monoinstitutional study (trial IEO#183) was undertaken in ER-positive breast cancer patients to compare the activity of tamoxifen at 5 mg/day or 1 mg/day with that of the standard dose of 20 mg/day in a randomized, presurgical, double-blind three arm trial by using posttreatment Ki-67 LI as a the main surrogate end point of antitumor effect. A loading dose of 20 mg on day 1 was applied in all arms to avoid differences in time to steady-state concentrations. The study showed no difference among tamoxifen doses on the primary end point Ki-67 reduction [12] . Briefly, tumor biopsy specimens and blood samples were taken before the systemic treatment began and again at the time of surgery to measure the changes in tissue Ki-67 LI and circulating biomarkers of estrogenic activity of tamoxifen, including insulin-like growth factor-I, sex hormone-binding globulin, lipids, antithrombin III, fibrinogen and hsCRP, all of which showed a dose-response relationship [12] . Women were included in the study if they met the following criteria: palpable tumor <5 cm (by mammography or ultrasound) suitable for an adequate core biopsy, N 0-1 , M 0 ; age 45 years or older; histological confirmation of an ER-positive or progesterone receptor (PgR)-positive (i.e. at least 20% positive cells by immunohistochemistry) breast cancer; performance status = 0. Both pre-and postmenopausal women groups of women were included in the study.
A core-cut biopsy of the primary tumor was obtained using a 14-gauge needle before the first dose of tamoxifen was taken, and a representative sample of the tumor was obtained at the time of surgery. Both samples were fixed in 10% neutral-buffered formalin for 6-12 h before being embedded in paraffin. Serial sections (2-3 l thick) were cut and stained with hematoxylin and eosin and immunostained for ER, PgR, Ki-67 and HER2/ neu in different batches, as previously described [13] , using specific primary mouse monoclonal antibodies to ER (clone 1D5, 1/100 dilution; Dako, Glostrup, Denmark), PgR (clone 1A6, 1/800 dilution; Dako), Ki-67 (clone Mib-1, 1/200 dilution; Dako) and a rabbit polyclonal antibody to the human epidermal growth factor receptor 2 (HER2)/neu protein (1/3200 dilution; Dako) for 30 min at room temperature with an automatic immunostainer (Autostainer; Dako). ER, PgR and Ki-67 immunostaining results were recorded as the percentage of immunoreactive cells over the total number of invasive neoplastic cells in the core biopsy specimens, or over at least 2000 tumor cells randomly selected from the periphery of each of the invasive carcinoma in the surgical specimens. HER2/neu immunoreactivity was evaluated as previously described [14] . Peritumoral vascular invasion was graded in three levels as previously described [15] . The designated pathologist was blinded to the treatment groups.
follow-up and survival update
While survival data were not among the initial protocol study end points, the majority of participants were actively followed-up with at least an annual visit at the Institute. For those women who were not seen directly at the coordinating center, a telephone call was carried out semiannually to ascertain disease and vital status. Disease-free survival was defined as time from randomization to the next invasive breast cancer event, i.e. disease recurrence at local, regional or distant site, a new contralateral breast cancer or death. All subjects with a disease recurrence were seen at the Institute in order to have a centrally reviewed clinical confirmation of disease.
statistical analyses
Median values, interquartile (IQ) ranges and nonparametric Wilcoxon and Kruskall-Wallis tests were presented to investigate differences in Ki-67 LI according to tumor variables. Chi-square or Fisher's exact tests were used to analyze the association between categorical variables.
Time to death and time to recurrence were defined as the time from surgery until the event of interest according to recently proposed definitions for efficacy end points [16] . All patients alive or free of disease at last follow-up date were considered right censored. Overall survival and disease-free survival curves were estimated by the Kaplan-Meier method. The log-rank and linear rank tests were used to compare survival time between groups and to evaluate linear trends. A Cox proportional hazards model was used to identify independent predictors of survival, with adjustment for relevant clinical covariates. Quartiles used to evaluate trends for Ki-67 were calculated from a database of 6853 patients analyzed at the Institute with ER positive or PgR positive; N 0-1 , M 0 breast cancer who underwent surgery from 2004 to 2007. The current sample followed a similar distribution.
All statistical tests were two-sided, and P < 0.05 was considered statistically significant. The statistical analyses were carried out with the Statistical Analysis System Version 8.2 (SAS Institute, Cary, NC) and the R (http://cran.r-project.org/) software with the Harrel's design and Hmisc libraries.
results
The main tumor characteristics are summarized in Table 1 . There were no differences among the subjects randomly assigned to the three tamoxifen dose groups. Median age was 60 years and 74% were postmenopausal. Stage pT 1 tumors represented 55% of the whole population. Mean tamoxifen treatment duration before surgery was 27 days in all three groups. Adjuvant treatment decision making was based on St Gallen risk categories at that time [17] . The main types of adjuvant treatments were the following: aromatase inhibitors or tamoxifen for 5 years in postmenopausal women and LH-RH agonists and tamoxifen in pre-and perimenopausal women. Chemotherapy, mainly four cycles of adriamycin and cyclophosphamide (AC) or six cycles of cyclophosphamide, methotrexate and fluoruracil (CMF), was given to patients with pathological node-positive disease and was evenly distributed among the three arms (46%, 49% and 55% in the 1, 5 and 20 mg day/arm, respectively). Trastuzumab was administered to a minority of women participating in the HERA trial. There were no significant differences in the prevalence of chemotherapy among the three treatment groups.
The association between the level of Ki-67 LI before and after tamoxifen treatment and a number of conventional prognostic or predictive factors is shown in Table 2 . Post-tamoxifen Ki-67 LI showed a significant association with ER expression, in as much as tumors with ER expression below the median value of 90% had a median Ki-67 LI of 16% (IQ range 11-25) compared with 10% (IQ range 6-15) in women with ER ‡ 90% (P = 0.001). Pre-and post-tamoxifen Ki-67 was found to be significantly associated with high tumor grade (P < 0.001 and P = 0.005, respectively) and with median age <60 years (P = 0.01 and P = 0.002, respectively). Furthermore, posttamoxifen Ki-67 LI was significantly higher in premenopausal women (P < 0.001). The reduction in Ki-67 LI was higher in tumors with ER > 90% and in women aged <60 years. No association was found with pT, pN and occurrence of peritumoral vascular invasion.
The associations of baseline and post-tamoxifen Ki-67 LI with disease recurrence and overall mortality are shown in Table 3 . At the current median follow-up time of >7 years, recurrence-free survival was 76% and overall survival was 92%. A total of 18 invasive neoplastic events were observed (6 loco-regional recurrences, 8 distant metastases, 1 contralateral breast cancer and 3 second neoplasms other than breast). In addition, there were 10 deaths, 8 due to breast cancer, 1 to a second neoplasm and 1 to a stroke. Baseline and post-tamoxifen Ki-67 LI was significantly higher in relapsed patients (median 21% versus 14%, P = 0.031; and 20% versus 12%, P = 0.001, respectively).
The log-rank test for trend suggested a prognostic association with recurrence-free survival for baseline Ki-67 LI according to our Institutional breast cancer database quartiles (P = 0.04). Post-tamoxifen Ki-67 LI categorized in quartiles, £13% (n = 68), 14%-19% (n = 19), 20%-29% (n = 17), ‡30% (n = 12), showed a clear predictive trend on recurrence-free survival in univariate analysis (log-rank P-trend = 0.0001, Figure 1, top) . Nodal status or menopausal status or neoadjuvant tamoxifen dose group or any adjuvant treatment had no impact on disease recurrence in univariate or multivariate analysis (data not shown).
Moreover, whereas baseline Ki-67 LI (categorized as ‡20% versus 0%-19%) was not a significant prognostic factor of overall death in univariate analysis (log-rank P = 0.13), posttamoxifen Ki-67 LI was a significant predictor of death since women who died because of the disease had a median posttamoxifen Ki-67 LI of 25.5% (IQ range 15-35.5) compared with 12% (IQ range 7.5-18) in those who were alive (P = 0.009, Table 3 ). Overall survival according to the median post-treatment Ki-67 LI cut-off value of 20% is shown in Figure 1 , bottom (log-rank P = 0.006).
In multivariate Cox analysis for recurrence-free survival, adjusted for pathological T and peritumoral vascular invasion, women with post-treatment Ki-67 LI in the second, third and top quartile had a recurrence hazard ratio (HR) of 2.92 [95% confidence interval (CI) 0.95-8.96], 4.37 (95% CI 1.56-12.25) and 6.05 (95% CI 2.07-17.65), respectively (P-trend < 0.001, Table 4 ). The model predicted a risk of disease recurrence of 2.2% (95% CI 0.99-4.7, P = 0.076) per point increase in baseline Ki-67 LI and of 5.0% (95% CI 2.3-7.7, P < 0.001) per point increase in post-treatment Ki-67 LI. Figure 2 illustrates the linear relationship between post-treatment Ki-67 LI and log(HR) for recurrence-free survival based on a multivariable Cox regression model, using the same cut-off values shown in Table 4 (horizontal segments).
When the variation in Ki-67 LI was used in place of the absolute level of post-treatment Ki-67 LI in the multivariable model, the HR decreased to 1.028 (95% CI 0.987-1.070, P = .19). When both baseline and post-treatment Ki-67 LI were entered into the multivariable model, the HR for baseline Ki-67 LI was 1.007 (95% CI 0.975-1.041) and the HR for posttreatment Ki-67 LI was 1.034 (95% CI 1.001-1.068), indicating that baseline values were not significantly associated with recurrence-free survival.
In a multivariate Cox analysis for overall survival, adjusted for ER expression level and pathological T, the risk of death was 5.5 times higher (95% CI 1.26-23.16) in women with posttamoxifen Ki-67 LI ‡20% than in those with Ki-67 LI <20% (P-trend = 0.006). The model predicted a risk of death of 4.5% (95% CI 0.9-9.6) per point increase in baseline Ki-67 LI (P = 0.066) and of 5.7% (95% CI 1.1-10.4) per point increase in post-tamoxifen Ki-67 LI (P-trend = 0.014; Figure 1 , bottom).
discussion
The availability of a surrogate biomarker that can prognosticate ER-positive breast cancer outcome based on its response to neoadjuvant treatment would be of great value to tailor an adjuvant treatment to the individual patient and to reliably screen new agents in a cost-effective manner. Dowsett et al. [6] have recently shown that Ki-67 LI after 2 weeks of neoadjuvant treatment with either tamoxifen or anastrozole or their combination improved the prediction of recurrence-free survival over baseline Ki-67 LI after a median of 3 years in postmenopausal women participating in the IMPACT trial [18] . Likewise, Ellis et al. [7] have shown that postmenopausal patients with pathological stage 1 or 0 disease after neoadjuvant endocrine therapy with aromatase inhibitors or tamoxifen given for 4 months and a low-risk biomarker profile in the surgical specimen, including lower Ki-67 expression, had a lower risk of relapse and prolonged breast cancer-specific survival and were therefore unlikely to benefit from adjuvant chemotherapy. Given the important clinical implications of these findings, independent confirmation in different series with inclusion of premenopausal women and overall mortality as an additional end point would strongly support the use of post-treatment Ki-67 LI as a reliable surrogate biomarker of disease outcome.
Our findings indicate that Ki-67 LI after 4 weeks of neoadjuvant tamoxifen predicts recurrence-free and overall survival significantly better than baseline Ki-67 LI. Specifically, whereas pretreatment Ki-67 per point increase was associated with a nonsignificant 2% increased risk of recurrence, posttamoxifen Ki-67 point increase predicted a 5% significant increased risk of recurrence. Likewise, overall mortality, mostly due to breast cancer, was better predicted by post-tamoxifen Ki-67 LI than by baseline Ki-67 LI, although both variables were significant survival prognosticators, with a nearly 6% increased risk of death per point increase in post-tamoxifen Ki-67 LI. Thus, the model predicted that a 3% absolute decrease in Ki-67 LI after short-term tamoxifen (e.g. from 18% to 15%) may be considered a clinical success as it is associated with a 15% relative decrease of recurrence and nearly a 18% decrease of death, a meaningful clinical accomplishment. Importantly, our findings derive from a patient population with average tumor size (55% were stage T 1 and average tumor size was 2.6 cm) so they are applicable to the majority of breast cancers and not only to large tumors requiring shrinkage by neoadjuvant treatment to perform conservative surgery.
The critical importance of proliferation in ER-positive breast cancer and its decrease after hormonal manipulation is consistent with recent data from Viale et al. [19] in the BIG-1-98 trial, where the prognostic effect of higher baseline Ki-67 on recurrence-free survival was highly significant and the magnitude of the benefit of letrozole over tamoxifen was higher in tumors with Ki-67 LI greater than the median value of 11%. Altogether these findings confirm that decrease in proliferation is a major mechanism of endocrine therapy in breast cancer, as confirmed by gene signatures that represent proliferation such as those included in the 21 recurrence score [3] and the distinction between luminal A and B tumors that have been shown to be important for prognosis of ER-positive breast cancer [20] . It will be interesting to see whether pre-versus post-treatment response to this gene expression profiles may further increase the prognostic and predictive value of the presurgical model compared with Ki-67 LI.
Our findings should be interpreted with caution, given the limited number of events, especially for overall death, that was based on 10 events only. Nevertheless, they are consistent with prior studies [6, 7] and therefore support the notion that posttreatment Ki-67 LI is a reliable marker of endocrine responsiveness that can allow selection of endocrine responsive patients who may not benefit for additional chemotherapy. A large randomized clinical trial (POETIC) is currently assessing this approach in postmenopausal women with the use of an aromatase inhibitor [6] . Our findings provide evidence that also tamoxifen can be used to this purpose, with the inclusion of premenopausal women, thus expanding the potential patient population. A simple and unexpensive change in clinical practice with the introduction of short-term window-of-opportunity presurgical trials of hormonal treatment may thus provide a powerful tool to assess hormonal responsiveness in vivo. This simple method should be compared with gene expression profiles that are currently being validated as chemotherapy decision makers in ER-positive breast cancer [21, 22] . Initial findings seem to reveal that a reliable immunohistochemistry (IHC) method to assess baseline ER, PgR, Ki-67 and HER2/neu may not be inferior to Genomic Health Inc. (GHI) recurrence score in predicting disease outcome [23] . Thus, tumor response to Ki-67 LI in conjunction with other molecular markers under investigation might even be superior than baseline gene signatures in selecting the most appropriate adjuvant treatment for an individual patient.
The predictive value of Ki-67 response on survival indirectly reinforces the notion that low-dose tamoxifen is a plausible therapeutic alternative to the standard dose as no difference in Ki-67 LI decrease among 1, 5 and 20 mg day of tamoxifen was noted in our previous study [12] . Admittedly, our study had limited power to detect differences among doses on recurrence-free and particularly overall survival. However, given the good prognosis of ductal intraepithelial neoplasia (DIN), and the previous finding that the mean tissue concentrations of tamoxifen and metabolites with 5 mg day were all above the in vitro IC50 [12, 24] , a dose of 5 mg day of Table 4 . HRs were adjusted for pT and peritumoral vascular invasion. The reference category of Ki-67 is 0%-14%.
original article Annals of Oncology tamoxifen has been adopted as the standard treatment of DIN at the Institute [25] , and a phase III trial of tamoxifen 5 mg day in women on postmenopausal hormone therapy is ongoing [26] .
Our findings strengthen the notion that short-term response of Ki-67 LI may be a valid surrogate to screen novel agents and to compare new drugs with standard endocrine treatments of breast cancer. Given the increasing resource limitations, there is urgent need to design more efficient clinical studies that do not require huge numbers of subjects and many years of follow-up. Both pharmaceutical industries and academic institutions are actively searching for valid surrogates that may allow a rapid and affordable assessment of the activity of novel compounds in randomized phase II trials before proceeding to a definitive phase III trial.
In conclusion, our findings indicate that Ki-67 LI response after short-term presurgical tamoxifen is a better predictor of invasive disease-free survival and overall survival than baseline Ki-67 LI in women with ER-positive breast cancer. These findings further support its use to personalize adjuvant treatment and to screen novel drugs in a cost-effective manner.
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